COVID-19 Prevention
Conditions
Keywords
Sputnik, Gamaleya
Brief summary
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Сov-2 Infection in Indian Healthy Subjects.
Detailed description
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Сov-2 Infection in Indian Healthy Subjects. In phase II trial, 100 subjects of immunogenicity group will be enrolled in 3:1 (Test:Placebo) ratio. These 100 subjects will be assessed for safety and immunogenicity outcomes till Day 28 post the first dose of investigational medicinal product (IMP)/placebo administration and will continue with study assessments till Day 180. Safety and immunogenicity data collected till Day 28 will be submitted to the regulatory authority for recommendation to proceed with Phase III recruitment. In Phase III trial, 1500 subjects will be enrolled and randomized in the ratio of 3:1 (Gam-COVID--Vac : Placebo). Each subject will participate in this adaptive study phase II/III clinical trial for 180±14 days after the first dose of the IMP/placebo and will have one screening visit and seven on-site visits during the trial period. The IMP/placebo will be administered intramuscularly during vaccination Visits 1 and 3 (Day 1 and Day 21±2). The observation Visits 2, 4, 5, 6, and 7 will be made on Day 19±2, Day 28±2, Day 42±2, Day 90±7, and Day 180±14, respectively. During the observation visits, vital indicators will be assessed in all subjects and changes in the subjects' condition and well being compared to the previous visit will be recorded. The schedule of examination procedures is mentioned in the Schedule of Event tables. Additionally, the subjects will be able to have remote consultations with the study physician through the weekly telephonic follow-up. Blood samples will be taken from immunogenicity group of phase II (all 100) and phase III (284 out of 1500) trials during the following visits to assess the immunogenicity parameters.
Interventions
BIOLOGICALGam-COVID-Vac
Vaccine for intramuscular injection
OTHERPlacebo
Placebo comparator
Sponsors
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Russian Direct Investment Fund
CRO: JSS Medical Research India Pvt. Ltd.
Dr. Reddy's Laboratories Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Written informed consent of a subject to participate in the trial 2. Males and females aged 18+ years 3. Negative human immunodeficiency virus (HIV 1 & 2) and hepatitis B and C test results 4. Negative immunoglobulin M (IgM) and immunoglobulin G (IgG) SARS-CoV-2 antibodies through enzyme immunoassay test result 5. Negative COVID-2019 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) test result at the screening visit (72 hours prior to Visit 1 \[Day 1\]) 6. No COVID-2019 in the medical history 7. History of no contact with COVID-2019 persons within at least 14 days before the enrolment (according to subjects) 8. Consent for using effective methods of contraception during the entire trial 1 9. Negative urine pregnancy test at the screening visit (for child-bearing age women) 10. No evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history 11. No acute infectious and/or respiratory diseases within at least 14 days before the enrolment.
Exclusion criteria
1. Any vaccination/immunization within 30 days before the enrolment 2. Steroids (except hormonal contraceptives) and immunoglobulins or other blood products therapy not finished 30 days before the enrolment 3. Immunosuppressors therapy finished within 3 months before the enrolment 4. Pregnancy or breast-feeding 5. Acute coronary syndrome or stroke suffered less than one year before the enrolment 6. Tuberculosis, chronic systemic infections 7. Drug allergy (anaphylactic shock, Quincke edema, polymorphic exudative eczema, atopy, serum disease),hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study product components, acute exacerbation of allergic diseases on the enrolment day 8. Subjects who are on drugs that could have potential drug interactions with adenovirus vaccine 9. Medical history of malignancy 10. Donated blood or plasma (450+ mL) within 2 months before the enrolment 11. Splenectomy in the medical history 12. Neutropenia (absolute neutrophil count less than 1,000 mm3), agranulocytosis, significant blood loss,severe anaemia (haemoglobin less than 80 g/L), immunodeficiency including autoimmune disorders in the medical history within 6 months before the enrolment 13. Active form of a disease caused by the HIV and hepatitis B or C 14. Anorexia, protein deficiency of any origin 15. Tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the IMP or placebo administration 16. Alcohol or drug addiction in the medical history. 17. Participation in any other interventional clinical trial within 1 month prior to the Screening 18. Any other medical condition that would limit the participation of the subject as per Investigator discretion 19. Study centre staff or other employees directly involved in the trial and their families 20. Subjects contraindicated for vaccination
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | For Phase II study - at Day 28; For Phase III study - till day 180 after first dose | For Phase II study - - Incidence & severity of adverse events (AEs) after first dose of IMP/Placebo For Phase III study - \- Incidence of related serious adverse events (SAEs) following vaccination during the study |
| Immunogenicity | For Phase II study - Day 28 after first dose | For Phase II study - \- Seroconversion rate of SARS-CoV-2 glycoprotein-specific antibodies in immunogenicity group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | Baseline to Day 180 | Incidence and severity of adverse events after injecting the first dose of the IMP/placebo Incidence of SAE following vaccination |
| Immunogenicity assessment | Baseline, Day 21, Day 28, Day 42, Day 90, and Day 180 | Seroconversion rate of SARS-CoV-2 glycoprotein-specific antibodies in immunogenicity group Seroconversion rate of SARS-CoV-2 virus-neutralizing antibodies in immunogenicity group |
| Percentage of subjects with mild, moderate, severe coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose of the vaccine/placebo | Baseline to Day 180 | Comparing percentage of subjects developing COVID-19 disease between Gam-COVID-Vac combined vector vaccine and placebo based on severity course |
| Incidence of coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose in trial subjects | Baseline to Day 180 | Comparing incidence of COVID-19 disease between Gam-COVID-Vac combined vector vaccine and placebo |
Countries
India
Outcome results
None listed